Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-04 6:57 pm Purchase |
2025-03-28 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
TANG CAPITAL MANAGEMENT LLC | 2,178,609 5.200% |
2,178,609 (New Position) |
Filing History |
| 2025-02-14 3:45 pm Sale |
2024-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Fairmount Funds Management LLC | 0 0.000% |
-3,204,841 (Position Closed) |
Filing History |
| 2024-11-14 4:32 pm Purchase |
2024-09-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 1,582,635 3.900% |
1,582,635 (New Position) |
Filing History |
| 2024-11-14 4:15 pm Purchase |
2024-09-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Fairmount Funds Management LLC | 3,204,841 7.900% |
3,204,841 (New Position) |
Filing History |
| 2024-11-13 4:30 pm Purchase |
2024-09-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Rubric Capital Management LP | 2,419,103 5.960% |
2,419,103 (New Position) |
Filing History |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BLACKROCK INC BLK |
3,815,656 9.400% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Sale |
2024-09-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BLACKROCK INC BLK |
3,815,656 9.400% |
-376,790 (-8.99%) |
Filing |
| 2024-10-08 5:29 pm Purchase |
2024-10-04 | 13D | Kiniksa Pharmaceuticals, Ltd. KNSA |
Baker Bros. Advisors LP | 3,151,029 7.700% |
3,151,029 (New Position) |
Filing History |
| 2024-04-05 12:21 pm Purchase |
2024-03-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BLACKROCK INC BLK |
4,192,446 10.500% |
1,011,858 (+31.81%) |
Filing |
| 2024-02-14 4:39 pm Purchase |
2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 3,879,426 9.900% |
338,125 (+9.55%) |
Filing History |
| 2024-02-14 3:46 pm Purchase |
2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Fairmount Funds Management LLC | 2,883,221 8.100% |
740,169 (+34.54%) |
Filing History |
| 2024-02-13 5:07 pm Sale |
2023-12-29 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
The Vanguard Group | 2,965,299 8.370% |
-261,592 (-8.11%) |
Filing History |
| 2024-02-12 06:06 am Purchase |
2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Rubric Capital Management LP | 2,907,501 8.210% |
2,907,501 (New Position) |
Filing History |
| 2024-01-25 1:48 pm Sale |
2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BLACKROCK INC BLK |
3,180,588 9.000% |
-247,153 (-7.21%) |
Filing |
| 2023-08-18 4:32 pm Purchase |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 3,541,301 9.900% |
917,377 (+34.96%) |
Filing History |
| 2023-08-10 4:15 pm Purchase |
2023-08-02 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Fairmount Funds Management LLC | 2,143,052 6.100% |
2,143,052 (New Position) |
Filing History |
| 2023-03-08 2:15 pm Sale |
2023-02-28 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BLACKROCK INC BLK |
3,427,741 4.900% |
-153,938 (-4.30%) |
Filing |
| 2023-02-14 4:08 pm Sale |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 2,623,924 7.600% |
-296,099 (-10.14%) |
Filing History |
| 2023-02-09 11:25 am Purchase |
2022-12-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
The Vanguard Group | 3,226,891 9.340% |
336,183 (+11.63%) |
Filing History |
| 2023-02-03 11:51 am Sale |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
PICTET ASSET MANAGEMENT SA | 1,234,193 3.570% |
-2,314,456 (-65.22%) |
Filing History |